Compare Peloton Interactive Inc (PTON) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Peloton Interactive Inc vs BIO-TECHNE Corp — how do they compare? Peloton Interactive Inc trades at $5.11 (market cap $2.16B), while BIO-TECHNE Corp trades at $72.44 (market cap $11.36B). The key difference: BIO-TECHNE Corp is far larger — about 5.3× Peloton Interactive Inc's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Peloton Interactive Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Peloton Interactive Inc for 37 Days and BIO-TECHNE Corp for 64 Days on average.
| PTON | TECH | |
|---|---|---|
Market Cap | $2.16B | $11.36B |
Volume | 11,369,487 | 5,390,331 |
Sector | Consumer Cyclical | Health |
52-Week High | $7.86 | $72.61 |
52-Week Low | $3.71 | $43.31 |
Typical Hold Time | 37 Days | 64 Days |
Enterprise Value | $2.66B | $11.39B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Peloton (PTON) trades at $5.06, up 4.33% on the day, but remains in a bearish technical trend. The company reported its first full-year net profit in fiscal 2026, with Q2 2026 EPS beating expectations at $0.13 versus $0.12, though revenue declined to $2.49B in 2025. Recent news highlights the launch of a new, more affordable Tread Flex treadmill and AI-powered coaching features as part of its turnaround strategy. Analyst consensus is a 'Buy' with a $8.00 price target, but negative shareholder equity and high debt levels pose significant risks.
The outlook is mixed; cost-cutting and new product launches support a path to sustained profitability, but subscriber declines, high leverage, and insider selling temper optimism. The stock offers speculative upside if execution improves, yet remains vulnerable to competitive pressures and macroeconomic headwinds. Investors should weigh the potential for operational turnaround against persistent financial and business model challenges.
Bio-Techne (TECH) trades at $72.45, down 0.11% on the day, near its 52-week high of $72.70. The stock shows bullish technical signals with strong moving average support. Fundamentally, the company maintains solid gross margins of 65.77% but faces declining net income margins, dropping from 24.6% in 2022 to 6.01% in 2025. Recent shareholder approval of Merck KGaA's acquisition at $73 per share provides a clear near-term catalyst.
The pending acquisition offers limited upside from current levels but provides downside protection. However, declining profitability trends and elevated valuation ratios (P/E 62.46) pose risks if the deal falls through. Investors should weigh the acquisition premium against fundamental deterioration in earnings quality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Peloton Interactive Inc
Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product revenue consists of sales of bike and tread and related accessories, associated fees for delivery and installation, and extended warranty agreements. Subscription revenue consists of revenue generated from monthly Connected Fitness Subscription and Digital Subscription. The company generates the majority of the revenue from the sale of Connected Fitness Products.
Read more on PTON →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
